Prestige Consumer Healthcare Inc has finalized the acquisition of the Breathe Right brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion. The deal, closed on June 15, 2026, was executed under the terms of an asset purchase agreement initially announced on March 20, 2026. The acquisition represents a strategic expansion for Prestige into the nasal strip category, with Breathe Right becoming the company's largest brand.

The transaction value includes approximately $900 million net of anticipated tax benefits valued at $150 million. Breathe Right, established in the 1990s, is recognized as the number one brand in the nasal strip category. Prestige financed the acquisition using a combination of available cash on hand and a completed financing for a new Term Loan B.

Transaction Details

The acquisition was structured as an asset purchase agreement. The following table outlines the financial components of the deal:

Strategic Impact

The addition of Breathe Right diversifies Prestige Consumer Healthcare's portfolio, which already includes brands such as Monistat, BC, and Clear Eyes. The company markets, sells, manufactures, and distributes consumer healthcare products across the U.S., Canada, Australia, and other international markets. This move is expected to strengthen Prestige's position in the over-the-counter healthcare sector.

The Schall Law Firm, a national shareholder rights litigation firm, is investigating Prestige Consumer Healthcare Inc. for potential violations of federal securities laws. The investigation focuses on whether the company issued false or misleading statements or failed to disclose material information to investors. This legal scrutiny comes after Prestige released its Q4 and full year 2026 financial results on May 13, 2026.

Prestige reported that for fiscal 2026, revenues decreased 4.5% organically compared to the prior year. The company also stated that its total company adjusted gross margin was 55.6% for the year, approximately flat compared to 55.8% in the previous year. Following this disclosure, shares of Prestige fell by 11.35% on the next trading day.

The Schall Law Firm represents investors globally and specializes in securities class action lawsuits and shareholder rights litigation. Investors who suffered losses in Prestige Consumer Healthcare Inc. are encouraged to contact the firm to discuss their rights. Brian Schall of The Schall Law Firm can be reached at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or by phone at 310-301-3335.

Key Financial Disclosures

Investors can also participate in the investigation through the firm's website at www.schallfirm.com or via email at bschall@schallfirm.com . This press release may be considered Attorney Advertising in some jurisdictions under applicable law and rules of ethics.